Clinical trialNCT04025372Active, not recruitingPhase 2Interventional

INTREPId (INTermediate Risk Erection PreservatIon Trial)

SponsorBrigham and Women's HospitalEnrollment234Prostate Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research study is comparing the use of a new form of hormonal therapy used with radiation as a possible treatment for intermediate risk prostate cancer. More specifically, this research would help determine whether this new form of hormonal therapy is as effective as the standard hormone therapy while also preserving erectile function.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Martin T. King, MD, PhD
Brigham and Women's Hospital
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Stamford Hospital
Stamford, Connecticut, United States
Beth Israel Deaconness Medical Center
Boston, Massachusetts, United States
Brigham and Women Hospital
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Dana-Farber/brigham and Women'S Cancer Center at Milford Regional Medical Center
Milford, Massachusetts, United States
Dana-Farber/brigham and Women'S Cancer Center in Clinical Affiliation With South Shore Hospital
South Weymouth, Massachusetts, United States
Washington University School of Medicine in St. Louis
St Louis, Missouri, United States
Xcancer Omaha / Urology Cancer Center
Omaha, Nebraska, United States
Nyu Long Island
Garden City, New York, United States
Nyu Langone Health
New York, New York, United States
Associated Medical Professionals of Ny
Syracuse, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bicalutamide →Darolutamide →GnRH Agonist

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 1 Jun 2020
Primary completion: 1 Oct 2027
Completion: 1 Mar 2028
Last update posted: 15 Dec 2025
Registered enrollment: 234
Registry id: NCT04025372

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.